Abstract
..
Main
..
RCT vs. Obs.
..
Feedback
Home
c19early.org COVID-19 treatment researchTocilizumabTocilizumab (more..)
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
 
Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
TMPRSS2 inh.⏵
Thermotherapy
Vitamins⏵
More⏵
 

Supplementary Data — Tocilizumab for COVID-19: real-time meta analysis of 46 studies

@CovidAnalysis, June 2025, Version 25V25
PDF
All
Studies
All
Treatments
Feedback
https://c19early.org/tzmeta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ SMACORE Colaneri (PSM) 18% 0.82 [0.07-3.41] death 5/21 19/91 Improvement, RR [CI] Treatment Control SMACORE Colaneri (PSM) 88% 0.12 [0.00-2.57] ICU 3/21 12/91 Ip 24% 0.76 [0.57-1.00] death 134 (n) 413 (n) Rojas-Marte 21% 0.79 [0.60-1.05] death 43/96 55/97 Campochiaro 53% 0.47 [0.18-1.20] death 5/32 11/33 Campochiaro -106% 2.06 [0.41-10.5] ventilation 4/32 2/33 Campochiaro 27% 0.73 [0.42-1.27] no disch. 12/32 17/33 Campochiaro 21% 0.79 [0.41-1.54] no improv. 10/32 13/33 Somers (PSW) 45% 0.55 [0.33-0.90] death 78 (n) 76 (n) Carvalho -166% 2.66 [0.32-5.52] death 5/29 4/24 Maeda 0% 1.00 [0.27-3.72] death 23 (n) 201 (n) Gokhale 38% 0.62 [0.38-0.99] death 70 (n) 91 (n) Kewan -23% 1.23 [0.22-6.76] death 3/28 2/23 Kewan -40% 1.40 [0.80-2.43] no disch. 17/28 10/23 Kewan 30% 0.70 [0.43-1.15] ventilation time 28 (n) 23 (n) Kewan -57% 1.57 [0.84-2.93] hosp. time 28 (n) 23 (n) Pettit -71% 1.71 [1.00-2.91] death 29/74 17/74 Guaraldi 62% 0.38 [0.17-0.83] death 13/125 73/179 Guaraldi 39% 0.61 [0.40-0.92] death/int. 125 (n) 179 (n) Menzella 45% 0.55 [0.22-1.35] death 41 (n) 38 (n) Menzella 56% 0.44 [0.22-0.89] death/int. 41 (n) 38 (n) Okoh -167% 2.67 [0.66-10.8] death 4/20 3/40 Okoh -344% 4.44 [1.34-14.8] ICU 10/30 3/40 Guisado-Vasco -140% 2.40 [1.13-5.11] death 132 (n) 475 (n) Rossi (PSM) 64% 0.36 [0.18-0.70] death 84 (n) 84 (n) Rossi (PSM) 60% 0.40 [0.23-0.70] death/int. 84 (n) 84 (n) Patel 9% 0.91 [0.45-1.83] death 21 (n) 21 (n) Patel 33% 0.67 [0.22-2.03] death 4/21 6/21 Patel -11% 1.11 [0.45-2.74] death 7/21 6/20 Chilimuri 60% 0.40 [0.20-0.77] death/int. 83 (n) 685 (n) Kimmig -82% 1.82 [0.96-3.47] death 19/54 11/57 Masiá 80% 0.20 [0.04-0.93] death 2/76 8/62 Masiá 8% 0.92 [0.38-2.24] ICU 9/76 8/62 Masiá -44% 1.44 [1.18-1.77] hosp. time 76 (n) 62 (n) Masiá (PSM) -68% 1.68 [0.36-7.81] viral+ 29 (n) 29 (n) Langer-Gould -117% 2.17 [0.05-5.56] death 24/52 9/41 OT​1​ Biran (PSM) 29% 0.71 [0.56-0.89] death 205 (n) 416 (n) Tsai (PSM) 0% 1.00 [0.57-1.75] death 18/66 18/66 Roumier 32% 0.68 [0.31-1.48] death 49 (n) 47 (n) Roumier 42% 0.58 [0.36-0.94] ventilation 49 (n) 47 (n) Roumier 45% 0.55 [0.36-0.82] no disch. 49 (n) 47 (n) Hill 43% 0.57 [0.21-1.52] death 43 (n) 45 (n) Hill 8% 0.92 [0.38-2.22] no improv. 43 (n) 45 (n) Canziani 18% 0.82 [0.42-1.58] death 64 (n) 64 (n) TOCICOV Ruiz-Antorán (PSW) 26% 0.74 [0.62-0.89] death 268 (n) 238 (n) BACC Bay Stone (DB RCT) -52% 1.52 [0.41-5.61] death 9/161 3/82 BACC Bay Stone (DB RCT) 35% 0.65 [0.26-1.62] ventilation 11/161 8/82 BACC Bay Stone (DB RCT) 17% 0.83 [0.38-1.81] death/int. 17/161 10/82 BACC Bay Stone (DB RCT) -11% 1.11 [0.59-2.10] progression 31/161 14/82 Wang (RCT) 27% 0.73 [0.32-1.66] progression 7/24 8/20 Wang (RCT) 54% 0.46 [0.09-2.32] no recov. 2/34 4/31 Wang (RCT) 79% 0.21 [0.05-0.87] no recov. 2/24 8/20 Wang (RCT) -8% 1.08 [0.92-1.28] hosp. time 34 (n) 31 (n) Wang (RCT) -6% 1.06 [0.88-1.28] viral time 34 (n) 31 (n) Gupta 29% 0.71 [0.56-0.92] death 433 (n) 3,491 (n) RCT-TCZ-COVID-19 Salvarani (RCT) -110% 2.10 [0.20-22.6] death 2/60 1/63 RCT-TCZ-COVID-19 Salvarani (RCT) -26% 1.26 [0.41-3.91] ICU 6/60 5/63 RCT-TCZ-COVID-19 Salvarani (RCT) -26% 1.26 [0.41-3.91] no disch. 6/60 5/63 RCT-TCZ-COVID-19 Salvarani (RCT) -5% 1.05 [0.59-1.86] no disch. 17/60 17/63 CORIMUNO-TOCI-1 Hermine (RCT) 7% 0.93 [0.36-2.42] death 7/63 8/67 CORIMUNO-TOCI-1 Hermine (RCT) -24% 1.24 [0.44-3.49] death 7/63 6/67 CORIMUNO-TOCI-1 Hermine (RCT) 62% 0.38 [0.15-0.99] ventilation 5/63 14/67 CORIMUNO-TOCI-1 Hermine (RCT) 34% 0.66 [0.39-1.15] progression 15/63 24/67 EMPACTA Salama (DB RCT) -22% 1.22 [0.62-2.38] death 26/249 11/128 EMPACTA Salama (DB RCT) 44% 0.56 [0.33-0.97] death/int. 249 (n) 128 (n) TOCIBRAS Veiga (RCT) -130% 2.30 [0.94-5.61] death 14/65 6/64 TOCIBRAS Veiga (RCT) 1% 0.99 [0.65-1.49] no recov. 65 (n) 64 (n) Fisher -4% 1.04 [0.27-3.75] death 45 (n) 70 (n) Martínez-Sanz 35% 0.65 [0.19-2.25] death n/a n/a Martínez-Sanz 66% 0.34 [0.17-0.71] death n/a n/a Martínez-Sanz -21% 1.21 [0.65-2.23] death n/a n/a SAMI-COVID Rodríguez-.. (PSM) 78% 0.22 [0.05-0.96] death 88 (n) 176 (n) SAMI-COVID Rodríguez-.. (PSM) 58% 0.42 [0.19-0.92] death/int. 88 (n) 176 (n) COVACTA Rosas (DB RCT) -1% 1.01 [0.68-1.52] death 58/294 28/144 COVACTA Rosas (DB RCT) 24% 0.76 [0.53-1.09] ventilation 51/183 33/90 COVACTA Rosas (DB RCT) 41% 0.59 [0.37-0.94] ICU 27/127 23/64 COVACTA Rosas (DB RCT) 22% 0.78 [0.54-1.12] recov. time 294 (n) 144 (n) REMAP-CAP Gordon (RCT) 22% 0.78 [0.63-0.97] death 98/350 127/355 De Rosa -41% 1.41 [0.66-2.99] death 97 (n) 1,239 (n) COVINTOC Soin (RCT) 29% 0.71 [0.34-1.46] death 11/91 15/88 COVINTOC Soin (RCT) -4% 1.04 [0.52-2.09] ventilation 14/91 13/88 COVINTOC Soin (RCT) 30% 0.70 [0.30-1.67] progression 8/91 11/88 COVINTOC Soin (RCT) -7% 1.07 [0.91-1.27] ICU 71/91 64/88 RECOVERY Horby (RCT) 12% 0.88 [0.81-0.96] death 621/2,022 729/2,094 RECOVERY Horby (RCT) 21% 0.79 [0.69-0.92] ventilation 265/1,754 343/1,800 RECOVERY Horby (RCT) 14% 0.86 [0.81-0.92] no disch. 872/2,022 1,050/2,094 CORIMUNO-TOCI-2 Hermine (RCT) 33% 0.67 [0.30-1.49] death 49 (n) 43 (n) Ho -290% 3.90 [2.96-5.13] death Talaschian (DB RCT) -40% 1.40 [0.45-4.37] death 5/17 4/19 Talaschian (DB RCT) 47% 0.53 [0.17-1.59] no disch. 17 (n) 19 (n) Talaschian (DB RCT) -40% 1.40 [0.45-4.37] no recov. 5/17 4/19 Talaschian (DB RCT) -11% 1.11 [0.66-1.87] recov. time 17 (n) 19 (n) Yen -58% 1.58 [0.98-2.57] death 67 (n) 2,129 (n) COVIDOSE-2 Reid (RCT) -56% 1.56 [0.17-14.3] death 3/50 1/26 COVIDOSE-2 Reid (RCT) 66% 0.34 [0.01-7.92] death 0/25 1/26 COVIDOSE-2 Reid (RCT) -212% 3.12 [0.35-28.0] death 3/25 1/26 COVIDOSE-2 Reid (RCT) -2% 1.02 [0.59-1.77] recov. time 25 (n) 26 (n) COVIDOSE-2 Reid (RCT) 20% 0.80 [0.62-1.04] recov. time 25 (n) 26 (n) COVIDOSE-2 Reid (RCT) -40% 1.40 [0.89-2.20] recov. time 25 (n) 26 (n) Tocilizumab COVID-19 outcomes c19early.org June 2025 ​1​ OT: comparison with other treatment Favors tocilizumab Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0